Glucokinase – Pipeline Review, H2 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Glucokinase – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage.

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Type 2 Diabetes, Diabetes, Obesity and Type 1 Diabetes (Juvenile Diabetes).

The latest report Glucokinase – Pipeline Review, H2 2019, outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

• The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)
• The report reviews Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

• Introduction
• Report Coverage
• Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Overview
• Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Therapeutics Development
• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Therapeutics Assessment
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Companies Involved in Therapeutics Development
• Eli Lilly and Co
• Hua Medicine Shanghai Ltd
• Ligand Pharmaceuticals Inc
• Merck & Co Inc
• Pfizer Inc
• Sanwa Kagaku Kenkyusho Co Ltd
• Teijin Pharma Ltd
• vTv Therapeutics Inc
• Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Drug Profiles
• dorzagliatin – Drug Profile
• Gene Therapy to Activate Glucokinase and Insulin for Diabetes and Obesity – Drug Profile
• LY-2608204 – Drug Profile
• PF-04937319 – Drug Profile
• Small Molecule to Activate Glucokinase for Type 2 Diabetes – Drug Profile
• Small Molecule to Activate Glucokinase for Type 2 Diabetes – Drug Profile
• Small Molecules 1 to Activate Glucokinase for Type 2 Diabetes – Drug Profile
• Small Molecules to Activate Glucokinase for Diabetes – Drug Profile
• Small Molecules to Activate Glucokinase for Type 2 Diabetes – Drug Profile
• TMG-123 – Drug Profile
• TTP-399 – Drug Profile
• Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Dormant Products
• Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Discontinued Products
• Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Product Development Milestones

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/gds791

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900